BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign
- 1 November 2021
- journal article
- letter
- Published by Elsevier BV in Gastroenterology
- Vol. 161 (5), 1715-1717.e1
- https://doi.org/10.1053/j.gastro.2021.06.076
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic TherapiesGastroenterology, 2021
- The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World DataClinical Infectious Diseases, 2021
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination SettingThe New England Journal of Medicine, 2021
- SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meetingGut, 2021
- Looking beyond COVID-19 vaccine phase 3 trialsNature Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- [ESTABLISHING A REGISTRY FOR INFLAMMATORY BOWEL DISEASE PATIENTS IN MACCABI HEALTHCARE SERVICES - JOINT PROJECT BETWEEN HOSPITALS, EPI-IIRN GROUP AND COMMUNITY MEDICINE].2018